Tenecteplase vs Medical Management in 4.5-24h LVO no Access to EVT

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

794

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

March 1, 2028

Study Completion Date

May 31, 2028

Conditions
Acute Ischemic StrokeLarge Vessel OcclusionTenecteplaseThrombolysis
Interventions
DRUG

TNK

a dose of 0.25 mg/kg (max 25 mg) administered as a bolus

DRUG

Standard medical treatment

antiplatelet drugs, anticoagulation or combinations of these treatment modality according to national and institutional guidelines.

Trial Locations (1)

Unknown

The First Affiliated Hospital of University of Science and Technology of China, Hefei

All Listed Sponsors
lead

The First Affiliated Hospital of University of Science and Technology of China

OTHER